We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





New 1-Minute COVID-19 Saliva Test Enables Swift Diagnosis of SARS-CoV-2 Infection

By LabMedica International staff writers
Posted on 03 Dec 2021

A new 1-minute COVID-19 saliva test for identifying individuals infected by SARS-CoV-2 has been designed for use at schools, events, companies, hotels, or airports, where swift diagnosis is key. More...

Abionic SA (Lausanne, Switzerland) has obtained the CE Mark (Conformité Européenne) for its new 1-minute COVID-19 saliva test using its cutting-edge testing platform, abioSCOPE. This allows Abionic to commercialize its ultra-fast test for identifying individuals infected by SARS-CoV-2 throughout the European Union. The test could signal a renaissance for the beleaguered hospitality sector which has lost millions of euros as bars, hotels and restaurants have borne the brunt of the pandemic restrictions. Equally, it could allow schools to remain open, offering continuity in education, and allow airports to streamline the passenger experience, and encourage travelers to fly again.

The clinical data for the ultra-fast IVD CAPSULE COVID-19 antigen test is based on studies including 119 individuals and demonstrated very high sensitivity for identifying infectious persons with viral loads measured by PCR of Ct<27, which is considered infectious. The ultra-fast IVD CAPSULE COVID-19 test using a saliva sample has been compared to Cobas 6800 UNICOVID saliva RT-PCR and showed very good correspondence. The test detects the presence of the nucleoprotein inside the SARS-CoV-2 virus, and thus can be used for assessing the contagiousness of an individual.

The use of the system is simple: after collecting saliva, the user mixes it with the reagent to reveal the nucleoprotein. The mix is then dispensed onto the IVD CAPSULE which is loaded onto the abioSCOPE reading device tray. After approximately 1 minute, the result is obtained directly on the screen of the abioSCOPE. The result is unequivocal and can be automatically transferred via secured data transmission protocol using the integrated ethernet port of the abioSCOPE.

Abionic's 1-minute COVID-19 saliva antigen quantification test also provides information about the potential contagiousness of the patient, allowing for preventive decision making immediately: "Is the patient representing a risk of spreading the disease?". It is designed to be used at schools, events, companies, hotels, or airports, where swift decision-making on COVID status is critical. Abionic is also developing a nasal / nasopharyngeal version of the IVD CAPSULE: COVID-19 on-site antigen diagnostic tests will allow healthcare professionals to issue an official COVID passport or extension of the COVID pass. It is designed to be used at hospitals, clinics, private practices, or pharmacies, where immediate high-quality results are of importance. The company is now preparing the listing on the EU common list.

"We are happy to offer the right tools to ensure COVID-free environments," stated Dr. Nicolas Durand, CEO of Abionic. "Getting a result in 1 minute re-opens the doors of places that were until now closed to many individuals. Obtaining CE Mark for our Saliva COVID-19 IVD CAPSULE is an important step in providing access to highly accurate ultra-fast tests throughout the European Union, and beyond. We are proud to actively participate to the global effort to get back to normality."

Related Links:
Abionic SA 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Integrated Biochemical & Immunological System
Biolumi CX8
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.